Clinical Trials Browser

Has results × Laryngeal Diseases × durvalumab × Clear all

NCT03529422 2025-07-20

Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN

Phase 2 Active not recruiting

18 enrolled 10 charts

Lymphoid Interstitial Pneumonia, Laryngeal Diseases, Mouth Neoplasms